1-7 of 7
Wynne Aherne
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Mike I. Walton, Paul D. Eve, Angela Hayes, Melanie R. Valenti, Alexis K. De Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth L. Smith, Kathy J. Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John C. Reader, Louis Chesler, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5650–5661.
https://doi.org/10.1158/1078-0432.CCR-12-1322
Published: 14 October 2012
View article titled, CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Open the PDF for CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Simon Pacey, Richard H. Wilson, Mike Walton, Martin M. Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik-Tobias Arkenau, Javier Moreno-Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johan S. de Bono, Florence Raynaud, Paul Workman, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1561–1570.
https://doi.org/10.1158/1078-0432.CCR-10-1927
Published: 15 March 2011
View article titled, A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6663–6673.
https://doi.org/10.1158/1078-0432.CCR-08-0376
Published: 16 October 2008
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors in another window
Journal Articles

Thymidylate Synthase Expression in Advanced Colorectal Cancer Predicts for Response to Raltitrexed

David C. Farrugia, Hugo E. R. Ford, David Cunningham, Kathleen D. Danenberg, Peter V. Danenberg, Jan Brabender, A. David McVicar, G. Wynne Aherne, Anthea Hardcastle, Keith McCarthy, Ann L. Jackman
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 792–801.
Published: 01 February 2003
View article titled, Thymidylate Synthase Expression in Advanced Colorectal Cancer Predicts for Response to Raltitrexed
Open the PDF for Thymidylate Synthase Expression in Advanced Colorectal Cancer Predicts for Response to Raltitrexed in another window
Journal Articles

Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules

G. Wynne Aherne, Anthea Hardcastle, Emma Ward, Donna Dobinson, Thomas Crompton, Melanie Valenti, Lisa Brunton, Ann L. Jackman
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (9): 2923–2930.
Published: 01 September 2001
View article titled, Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules
Open the PDF for Pharmacokinetic/Pharmacodynamic Study of ZD9331, a Nonpolyglutamatable Inhibitor of Thymidylate Synthase, in a Murine Model Following Two Curative Administration Schedules in another window
Journal Articles

Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues

Sarah J. Welsh, Jenny Titley, Lisa Brunton, Melanie Valenti, Paul Monaghan, Ann L. Jackman, G. Wynne Aherne
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2538–2546.
Published: 01 June 2000
View article titled, Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues
Open the PDF for Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues in another window
Journal Articles

Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of de Novo Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines

Matthew J. Barnes, Edward J. Estlin, Gordon A. Taylor, G. Wynne Aherne, A. Hardcastle, J. J. McGuire, Joanne A. Calvete, John Lunec, Andrew D. J. Pearson, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2548–2558.
Published: 01 September 1999
View article titled, Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of <em>de Novo</em> Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines
Open the PDF for Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of <em>de Novo</em> Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines in another window